EA201100814A1 - Фармацевтические формы применения, содержащие нифедипин или низолдипин и антагонист ангиотензина-ii и/или диуретик - Google Patents

Фармацевтические формы применения, содержащие нифедипин или низолдипин и антагонист ангиотензина-ii и/или диуретик

Info

Publication number
EA201100814A1
EA201100814A1 EA201100814A EA201100814A EA201100814A1 EA 201100814 A1 EA201100814 A1 EA 201100814A1 EA 201100814 A EA201100814 A EA 201100814A EA 201100814 A EA201100814 A EA 201100814A EA 201100814 A1 EA201100814 A1 EA 201100814A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diuretic
antagonist
nizoldipin
angiotenzine
pharmaceutical forms
Prior art date
Application number
EA201100814A
Other languages
English (en)
Other versions
EA025485B1 (ru
Inventor
Александр Куль
Эрих Брендель
Франк Бреккер
Адриан Функэ
Андреас Ом
Деннис Квезик
Томас Фолькмер
Original Assignee
Байер Шеринг Фарма Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41566078&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201100814(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Байер Шеринг Фарма Акциенгезельшафт filed Critical Байер Шеринг Фарма Акциенгезельшафт
Publication of EA201100814A1 publication Critical patent/EA201100814A1/ru
Publication of EA025485B1 publication Critical patent/EA025485B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Данное изобретение относится к фармацевтической форме применения, которая содержит комбинацию биологически активных веществ из нифедипина или низолдипина и как минимум одного антагониста ангиотензина-II и/или как минимум одного диуретика, отличающуюся тем, что нифедипин или низолдипин высвобождается контролируемо (модифицировано) в теле человека, а антагонист ангиотензина-II и/или диуретик быстро высвобождается (быстрое высвобождение (БВ)), а также к способу ее получения, к ее применению в качестве лекарственного средства, а также к ее применению для профилактики, вторичной профилактики или для лечения заболеваний.
EA201100814A 2008-11-27 2009-11-19 Фармацевтические формы применения, содержащие нифедипин или низолдипин и антагонист ангиотензина-ii и/или диуретик EA025485B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102008059206A DE102008059206A1 (de) 2008-11-27 2008-11-27 Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
PCT/EP2009/008232 WO2010060564A1 (de) 2008-11-27 2009-11-19 Pharmazeutische darreichungsform enthaltend nifedipin oder nisoldipin und einen angiotensin-ii antagonisten und/oder ein diuretikum

Publications (2)

Publication Number Publication Date
EA201100814A1 true EA201100814A1 (ru) 2011-10-31
EA025485B1 EA025485B1 (ru) 2016-12-30

Family

ID=41566078

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100814A EA025485B1 (ru) 2008-11-27 2009-11-19 Фармацевтические формы применения, содержащие нифедипин или низолдипин и антагонист ангиотензина-ii и/или диуретик

Country Status (36)

Country Link
US (1) US9993432B2 (ru)
EP (1) EP2370065B1 (ru)
JP (2) JP2012509918A (ru)
KR (1) KR101418632B1 (ru)
CN (2) CN106214659A (ru)
AR (1) AR073423A1 (ru)
AU (1) AU2009319362B2 (ru)
BR (1) BRPI0922306A2 (ru)
CA (1) CA2744515C (ru)
CL (1) CL2011001091A1 (ru)
CO (1) CO6382107A2 (ru)
CR (1) CR20110260A (ru)
CU (1) CU24065B1 (ru)
CY (1) CY1118183T1 (ru)
DE (1) DE102008059206A1 (ru)
DK (1) DK2370065T3 (ru)
DO (1) DOP2011000137A (ru)
EA (1) EA025485B1 (ru)
EC (1) ECSP11011052A (ru)
ES (1) ES2585731T3 (ru)
HR (1) HRP20160987T1 (ru)
HU (1) HUE029085T2 (ru)
IL (1) IL212599A (ru)
MX (1) MX2011005023A (ru)
MY (1) MY160000A (ru)
NZ (1) NZ593045A (ru)
PA (1) PA8849701A1 (ru)
PE (2) PE20110927A1 (ru)
PL (1) PL2370065T3 (ru)
PT (1) PT2370065T (ru)
SI (1) SI2370065T1 (ru)
SV (1) SV2011003905A (ru)
TW (1) TWI484957B (ru)
UA (1) UA103347C2 (ru)
UY (1) UY32260A (ru)
WO (1) WO2010060564A1 (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210595A1 (en) * 2009-01-14 2010-07-28 LEK Pharmaceuticals d.d. Active coating of pharmaceutical dosage forms
CN102274223B (zh) * 2010-06-12 2012-10-24 重庆市力扬医药开发有限公司 含替米沙坦和氨氯地平的复方制剂
EP2651399A2 (en) * 2010-12-13 2013-10-23 Purdue Pharma LP Controlled release dosage forms
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
JP5934610B2 (ja) * 2011-08-30 2016-06-15 第一三共ヘルスケア株式会社 イブプロフェンを含有するフィルムコーティング製剤
US9480681B2 (en) * 2011-09-23 2016-11-01 Emcure Pharmaceuticals Limited Controlled release formulations of nisoldipine
WO2013091574A1 (zh) * 2011-12-23 2013-06-27 天津泰普医药知识产权流转储备中心有限公司 包含坎地沙坦或其酯以及氯噻酮的药物组合物及其应用
KR20150007297A (ko) 2012-05-07 2015-01-20 바이엘 파마 악티엔게젤샤프트 니페디핀 및 칸데사르탄 실렉세틸을 포함하는 제약 투여 형태의 제조 방법
JP6304675B2 (ja) * 2012-07-18 2018-04-04 国立大学法人北陸先端科学技術大学院大学 炭酸脱水酵素阻害剤のスクリーニング方法
NZ744862A (en) * 2012-08-17 2019-06-28 Hoffmann La Roche Combination therapies for melanoma comprising administering cobimetinib and vemurafenib
KR101778050B1 (ko) * 2012-10-12 2017-09-13 이에이 파마 가부시키가이샤 칼슘 길항약／안지오텐신 ｉｉ 수용체 길항약 함유 의약 제제의 제조 방법
DK3043778T3 (da) * 2013-09-13 2017-11-27 Bayer Pharma AG Farmaceutiske sammensætninger, der indeholder refametinib
CN104758289B (zh) * 2015-03-09 2019-05-03 西安力邦制药有限公司 一种含美托法宗的复方降压药物组合及其应用
KR101710441B1 (ko) 2015-12-28 2017-02-28 신풍제약주식회사 안정성 및 용출성이 향상된 정제
PL3573620T3 (pl) 2017-01-25 2023-04-24 The George Institute for Global Health Kompozycje do leczenia nadciśnienia
DE102017008656B4 (de) 2017-09-15 2020-12-03 Glatt Maschinen- Und Apparatebau Ag Verfahren zur Regelung des Massen- oder Volumenstroms des Zerstäubergases einer Düse; Vorrichtung zur Regelung des Massen- oder Volumenstroms des Zerstäubergases einer Düse; Verwendung eines Verfahrens oder einer Vorrichtung zur Regelung des Massen- oder Volumenstroms des Zerstäubergases
CN107648240A (zh) * 2017-11-08 2018-02-02 罗昌兴 一种抗高血压药物复方制剂
US10905667B2 (en) 2018-07-24 2021-02-02 Bayer Pharma Aktiengesellschaft Orally administrable modified-release pharmaceutical dosage form
MX2021000904A (es) 2018-07-24 2021-03-31 Bayer Ag Forma de dosificacion farmaceutica administrable por via oral con liberacion modificada.
CA3107174A1 (en) 2018-07-24 2020-01-30 Bayer Aktiengesellschaft Pharmaceutical dosage form which can be administered orally and has modified release
WO2020021341A1 (en) * 2018-07-26 2020-01-30 The George Institute for Global Health Compositions for the treatment of hypertension
CN109557042B (zh) * 2018-11-26 2021-10-08 广东朗研科技有限公司 基于半导体镀纳米介孔金属薄膜结构及太赫兹波增强系统
CA3143958A1 (en) * 2019-06-18 2020-12-24 Strongbridge Dublin Limited Dichlorphenamide compositions and methods of use
CN113135915B (zh) * 2021-04-27 2022-12-09 湖北美林药业有限公司 一种氨苯蝶啶及氨苯蝶啶组合物制剂
CN114931559A (zh) * 2022-06-02 2022-08-23 南京白敬宇制药有限责任公司 硝苯地平缓释片优化包衣工艺方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670827C3 (de) 1967-03-20 1974-10-24 Bayer Ag, 5090 Leverkusen 4-(2'-Nitrophenyl)-2,6-dimethyl-3,5-dicarbmethoxy-1,4-dihydropyridin
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4576604A (en) * 1983-03-04 1986-03-18 Alza Corporation Osmotic system with instant drug availability
US4673405A (en) * 1983-03-04 1987-06-16 Alza Corporation Osmotic system with instant drug availability
US5082668A (en) 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
NZ206600A (en) 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
DK383086A (da) 1985-08-21 1987-02-22 Rohm & Haas (2-cyano-2-arylethyl)pyridiner, deres fremstilling og deres anvendelse som fungicider
US4842867A (en) 1986-05-09 1989-06-27 Alza Corporation Pulsed drug delivery of doxylamine
US4948592A (en) 1986-05-09 1990-08-14 Alza Corporation Pulsed drug delivery
DE3720757A1 (de) 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
US4931285A (en) 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
ES2044246T3 (es) 1989-02-11 1994-01-01 Bayer Ag Medicamentos con liberacion controlada del producto activo.
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
AU656551B2 (en) 1990-12-14 1995-02-09 Smithkline Beecham Corporation Angiotensin II receptor blocking compositions
US5160744A (en) 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US5178867A (en) 1991-08-19 1993-01-12 Alza Corporation Dosage form for delivering drug in short-time period
US5543154A (en) 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
CA2125251C (en) 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
TW483763B (en) 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
JP3220373B2 (ja) 1995-11-28 2001-10-22 バイエル薬品株式会社 持続性ニフエジピン製剤
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
JP3950175B2 (ja) 1997-05-30 2007-07-25 オスモティカ・コーポレイション 多層浸透デバイス
AU9202398A (en) * 1997-09-29 1999-04-23 Becton Dickinson & Company Injection device and drug cartridge for preventing cross-use of the device and drug cartridge
DE19747261A1 (de) 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
GB9722426D0 (en) 1997-10-23 1997-12-24 Univ London Pharmacy Controlled release formulations
DE19812688A1 (de) * 1998-03-23 1999-09-30 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
DE19901921C2 (de) 1999-01-19 2001-01-04 Boehringer Ingelheim Pharma Polymorphe von Telmisartan, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung eines Arzneimittels
WO2000059481A1 (en) 1999-04-06 2000-10-12 Pharmaquest Ltd. PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT
US20040115134A1 (en) 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
NZ518739A (en) * 1999-11-02 2004-12-24 Depomed Inc Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
DE19954421A1 (de) * 1999-11-12 2001-05-31 Lohmann Therapie Syst Lts Filmförmige Zubereitung zur biphasigen Freisetzung pharmakologisch wirksamer oder anderer Substanzen
US6569456B2 (en) 2000-01-13 2003-05-27 Osmotica Corp. Osmotic device containing diltiazem and an ACE inhibitor or diuretic
NZ525913A (en) 2000-11-21 2004-05-28 Sankyo Co A pharmaceutical composition
JP2002316928A (ja) * 2001-04-17 2002-10-31 Lion Corp コーティング錠及びコーティング錠のはがれを防止する方法
WO2003013609A1 (en) 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Sustained-release medicines
CA2464561A1 (en) 2001-10-25 2003-05-01 Depomed, Inc. Methods of treatment using a gastric retained losartan dosage
US20030161882A1 (en) 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
AU2003227472A1 (en) 2002-03-27 2003-10-08 Bayer Aktiengesellschaft Downsized core tablet containing nifedipine
JP3751287B2 (ja) * 2002-03-27 2006-03-01 バイエル薬品株式会社 小型化されたニフェジピン有核錠剤
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
TW200306799A (en) 2002-05-17 2003-12-01 Novartis Ag Combination of organic compounds
KR20100137023A (ko) * 2002-09-20 2010-12-29 안드렉스 랩스 엘엘씨 약제학적 정제
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
AR043395A1 (es) 2003-02-28 2005-07-27 Recordati Ireland Ltd Terapia de combinacion para la hipertension utilizando lercanidipina y un bloqueante de los receptores de angiotensina ii
US8029822B2 (en) 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
ATE457166T1 (de) 2003-07-24 2010-02-15 Wockhardt Ltd Orale zusammensetzungen zur behandlung von diabetes
WO2005070398A2 (en) 2004-01-23 2005-08-04 Ranbaxy Laboratories Limited Pharmaceutical compositions of candesartan cilexetil stabilized with co-solvents
EP1711168A2 (en) 2004-01-23 2006-10-18 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of candesartan cilexetil
WO2005084648A1 (en) 2004-02-27 2005-09-15 Ranbaxy Laboratories Limited Pharmaceutical compositions comprising candesartan cilexetil
TWI354569B (en) 2004-05-28 2011-12-21 Bristol Myers Squibb Co Coated tablet formulation and method
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
MY146830A (en) 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
DE102005031577A1 (de) * 2005-07-06 2007-01-11 Bayer Healthcare Ag Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
NZ554157A (en) * 2005-07-26 2010-12-24 Glaxo Smithkline Trading Services Ltd Pharmaceutical compositions comprising levetiracetam and process for their preparation
US20070128281A1 (en) * 2005-12-02 2007-06-07 Patel Hasmukh B Oral osmotic drug delivery system
BRPI0712532A2 (pt) * 2006-06-01 2013-04-02 Schering Plough Healthcare Prod Inc formulaÇÕes e composiÇÕes farmacÊuticas de fenilefrina para absorÇço colânica
WO2008035360A2 (en) 2006-06-13 2008-03-27 Alembic Limited Novel crystalline forms of candesartan cilexetil, candesartan, tritylated candesartan and tritylated candesartan cilexetil
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
WO2008045006A1 (en) 2006-10-11 2008-04-17 Fako Ilaclari A. S. Formulations of candesartan
US20100041644A1 (en) 2006-11-28 2010-02-18 Laboratorios Liconsa, S. A. Stabilized solid pharmaceutical composition of candesartan cilexetil
US20090093542A1 (en) * 2007-10-04 2009-04-09 Cooper Garth J S Copper antagonist compositions
US20100316711A1 (en) 2007-10-25 2010-12-16 Bayer Yakuhin ,Ltd. Nifedipine containing opress coated tablet and method of preparing same
AU2009308885A1 (en) * 2008-10-31 2010-05-06 Mcneil-Ppc, Inc. Osmotic tablet with a compressed outer coating
UY34856A (es) * 2012-07-03 2013-12-31 Bayer Pharma AG Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida

Also Published As

Publication number Publication date
AR073423A1 (es) 2010-11-03
CA2744515C (en) 2013-01-22
UY32260A (es) 2010-06-30
MX2011005023A (es) 2011-05-30
CU20110110A7 (es) 2012-01-31
PA8849701A1 (es) 2010-07-27
CY1118183T1 (el) 2017-06-28
DE102008059206A1 (de) 2010-06-10
CN106214659A (zh) 2016-12-14
TWI484957B (zh) 2015-05-21
EP2370065B1 (de) 2016-05-04
UA103347C2 (ru) 2013-10-10
WO2010060564A1 (de) 2010-06-03
MY160000A (en) 2017-02-15
US20120034272A1 (en) 2012-02-09
PE20110927A1 (es) 2011-12-28
EA025485B1 (ru) 2016-12-30
EP2370065A1 (de) 2011-10-05
US9993432B2 (en) 2018-06-12
NZ593045A (en) 2013-01-25
TW201031405A (en) 2010-09-01
CO6382107A2 (es) 2012-02-15
SI2370065T1 (sl) 2016-09-30
KR101418632B1 (ko) 2014-07-25
JP2015120734A (ja) 2015-07-02
CN102227216A (zh) 2011-10-26
CA2744515A1 (en) 2010-06-03
SV2011003905A (es) 2011-08-29
BRPI0922306A2 (pt) 2016-01-05
JP6017604B2 (ja) 2016-11-02
HRP20160987T1 (hr) 2016-11-18
CL2011001091A1 (es) 2011-10-28
CU24065B1 (es) 2014-12-26
AU2009319362A1 (en) 2010-06-03
IL212599A0 (en) 2011-07-31
HUE029085T2 (hu) 2017-02-28
ECSP11011052A (es) 2011-06-30
AU2009319362B2 (en) 2013-05-09
DOP2011000137A (es) 2011-10-15
DK2370065T3 (en) 2016-08-22
IL212599A (en) 2014-11-30
PE20142192A1 (es) 2014-12-12
PL2370065T3 (pl) 2016-11-30
KR20110093814A (ko) 2011-08-18
PT2370065T (pt) 2016-08-08
JP2012509918A (ja) 2012-04-26
ES2585731T3 (es) 2016-10-07
CR20110260A (es) 2011-09-12

Similar Documents

Publication Publication Date Title
EA201100814A1 (ru) Фармацевтические формы применения, содержащие нифедипин или низолдипин и антагонист ангиотензина-ii и/или диуретик
EA201390060A1 (ru) Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
EA201000897A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
WO2013186777A3 (en) Use of blocking agents of bone morphogenie protein (bmp) signaling for the treatment of neuroinflammatory and neurodegenerative diseases
UA109650C2 (xx) Біс-арилзв'язані арилтриазолони та їх застосування
EA201290131A1 (ru) Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
TN2011000263A1 (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
EA201300558A1 (ru) Соединения и способы для купирования боли
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
WO2015054619A3 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
EA201101709A1 (ru) Полициклические антагонисты рецепторов лизофосфатидной кислоты
EA201390821A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты и их применение
MY164581A (en) Purin derivatives for use in the treatment of fab-related diseases
EA200802204A1 (ru) Применение ингибиторов dpp iv
EA201890654A1 (ru) Терапевтические композиции для лечения вируса иммунодефицита человека
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
MY157564A (en) Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
WO2007003330A3 (de) Pharmazeutische darreichungsformen enthaltend eine wirkstoffkombination von nifedipin und/oder nisoldipin und einem angiotensin-ii antagonisten
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
WO2011151722A3 (en) Methods and compositions for oral pharmaceutical therapy
MA32224B1 (fr) Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales
EA201270747A1 (ru) Композиции и способы для профилактики и лечения ран
UA109359C2 (xx) Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
EA201170583A1 (ru) Новая композиция для лечения эссенциальной тромбоцитемии

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU